Abstract
Objective
The main objective of this study was to evaluate treatment patterns and to assess the relationship between diabetes mellitus-related vascular complications and the total medical/prescription drug costs in the elderly population using a large, national, self-insured employer database.
Methods
Type 2 diabetes patients who were ≥65 years of age were identified from a large, national, self-insured employer database. The study population included 9959 type 2 diabetes patients with an index date ranging from 1996 to 2001. Patients were enrolled for a minimum of 12 months, and so the enrollment period spanned the years 1996 to 2002. The date of the patients’ type 2 diabetes diagnosis was used as the index date for each patient. Vascular complications (cardiovascular, cerebrovascular, microvascular, and peripheral vascular) were grouped separately into a cohort hierarchy for analysis. The total annual healthcare costs (i.e. all claim costs, including prescription costs) were estimated for each group with adjustment for age, sex, and the severity of the complication. The hospitalization status was used as a measure of severity. Costs were also estimated for specific diabetes-related complications. All costs were reported in 2002 US dollars.
Results
The adjusted total annual costs for patients without hospitalizations ranged from $US4877 with no complications to $US12 271 with four complications. For patients with hospitalizations, the adjusted total annual costs ranged from $US18 839 with one complication to $US41 011 with four complications. The average annual costs per patient without/with hospitalizations for each vascular category were: cardiovascular, $US8664/$US23 224; cerebrovascular, $US10 352/$US24 279; microvascular, $US10 271/$US33 696; and peripheral vascular, $US10 925/$US28 369. The average annual costs per patient without/with hospitalizations for specific conditions were: hypertension, $US7642/$US17 978; stroke, $US15 349/$US25 333; end-stage renal disease, $US23 657/$US63 173; and lower limb amputation, $US53 286/$US52 434.
Conclusion
Type 2 diabetes complications in the elderly population create significant healthcare expenditure for employers, their beneficiaries, and third-party payors. Preventive strategies and better management of type 2 diabetes in elderly patients could reduce the occurrence of such complications and have remarkable cost-saving implications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lavigne JE, Phelps CE, Mushlin A, et al. Reductions in individual work productivity associated with type 2 diabetes. Pharmacoeconomics 2003; 21(15): 1123–34
American Diabetes Association. Total prevalence of diabetes and pre-diabetes [online]. Available from URL: http://www.diabetes.org/diabetes-statistics/prevalence.jsp [Accessed 2005 May 24]
Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging 2001; 18(1): 31–44
Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26(3): 917–32
Selby JV, Ray GT, Zhang D, et al. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997; 20: 1396–402
Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997 Dec; 78(6): 544–9
Gagliardino JJ, Martella A, Erchegoyen GS, et al. Hospitalization and re-hospitalization of people with and without diabetes in La Plata, Argentina: comparison of their clinical characteristics and costs. Diabetes Res Clin Pract 2004; 65: 51–9
Krop JS, Powe NR, Weiler WE, et al. Patterns of expenditures and use of services among older adults with diabetes. Diabetes Care 1998; 21(5): 747–52
Terpstra TL, Terpstra TL. The elderly type II diabetic: a treatment challenge. Geriatr Nurs 1998; 19: 253–9
Dornan TL, Peck GM, Dow JDC, et al. A community survey of diabetes in the elderly. Diabet Med 1992; 9: 860–5
Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci 2001; 56A(1): M5–M13
Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461–94
Gossain VV, Carella MJ, Rovner DR. Management of diabetes in the elderly: a clinical perspective. J Assoc Acad Minor Phys 1994; 5: 22–31
O’Brien JA, Shomphe LA, Kavanagh PL, et al. Direct medical costs of complications resulting from type 2 diabetes in the US. Diabetes Care 1998; 21(7): 1122–8
Ramsey SD, Newton K, Blough D, et al. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics 1999; 16(3): 285–95
Moses SE, Klein R, Klein BE. Risk factors of hospitalization in people with diabetes. Arch Intern Med 1999; 159: 2053–7
Rosenthal MJ, Fajardo M, Gilmore S, et al. Hospitalization and mortality of diabetes in older adults. Diabetes Care 1998; 21: 1320–9
Maciejewski ML, Maynard C. Diabetes-related utilization and costs for inpatient and outpatient services in the Veterans Administration. Diabetes Care 2004; 27 Suppl. 2: B69–73
Currie CJ, Williams DR, Peters JR. Patterns of in and out-patient activity for diabetes: a district survey. Diabet Med 1996 Mar; 13(3): 273–80
Smith NL, Maynard C. The burden of diabetes-associated cardiovascular hospitalizations in Veterans Administration (VA) and non-VA medical facilities. Diabetes Care 2004; 27 Suppl. 2: B27–32
Gu K, Cowie GC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care 1998; 21: 1138–45
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703–13
Bressler P, Bailey SR, Matsuda M, et al. Insulin resistance and coronary artery disease. Diabetologia 1996; 39: 1345–50
Kuusisto J, Mykkanen L, Pyorala K, et al. Hyperinsulinemic micro-albuminuria: a new risk indicator for coronary heart disease. Circulation 1995; 91: 831–7
Gordois A, Schuffham P, Shearer A, et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabet Complications 2004; 18: 18–26
Pernerger TC, Brancati FL, Whelton PK, et al. End-stage renal disease attributable to diabetes-mellitus. Ann Intern Med 1994; 121: 912–8
Dong FB, Manninen DL, Dasbach EJ, et al. The longitudinal cost end-stage renal disease in persons with diabetes in the United States [abstract]. Diabetes 2002; 51 Suppl. 2: A72
American Diabetes Association. Diabetes and retinopathy (eye complications) [online]. Available from URL: http://www.diabetes.org/diabetes-statistics/eyecomplications.jsp [Accessed 2004 Aug 19]
Nelzen O, Bergqvist D, Libdhagen A. A long term prognosis for patients with chronic leg ulcers: a prospective cohort study. Eur J Vasc Endovasc Surg 1997; 13: 500–8
Ollendorf DA, Kotsanos JG, Wishner WJ, et al. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 1998 Aug; 21(8): 1240–5
Acknowledgments
This research project was funded by Takeda Pharmaceuticals North America, Inc., and represents a joint research project by Takeda, Omnicare, Inc., Associates & Wilson, and Options and Choices, Inc. (OCI). Drs Rajagopalan and Iyer were employees of Takeda throughout the duration of the project. Partial results of the study were presented at the Annual Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) held in May 2004 in Washington, DC, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Erwin, G., Iyer, S., Rajagopalan, R. et al. Type 2 Diabetes Mellitus Treatment Patterns and Healthcare Costs in the Elderly Population. Dis-Manage-Health-Outcomes 14, 75–83 (2006). https://doi.org/10.2165/00115677-200614020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00115677-200614020-00002